Latest Information Update: 17 Feb 2010
At a glance
- Originator Sciele Pharma
- Developer Shionogi Pharma
- Class Antimigraines
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Migraine
Most Recent Events
- 16 Jun 2006 First Horizon Pharmaceutical Corporation is now called Sciele Pharma
- 23 Jun 2003 Phase-I clinical trials in Migraine in USA (unspecified route)